Cure
With advances in technology, decentralized trials are becoming a more viable option for some clinical trials. Jeffrey Zonder, M.D., hematologist and leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team, led the first decentralized trial at Karmanos. He shared how to determine if elements of some clinical studies can be safely moved to a virtual format.
Read the article here.